Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge

Key Takeaways

• Outsourced pharmaceutical supply chains can become harder to manage when production, testing, materials, documentation, and decision-making are distributed across multiple external partners.

• Supplier risk is operational risk, with pharmaceutical supply chain vulnerabilities tied to supplier relationships, raw-material quality, delivery reliability, information flow, stock visibility, and fragmented responsibilities.

• Quality-system maturity is essential to supply continuity, especially when outsourced manufacturing networks depend on multiple contract manufacturers, suppliers, and testing providers.

• Technology transfer and knowledge continuity are critical resilience factors because outsourced networks require product, process, analytical, quality, and operational knowledge to move reliably across organizations.

• Supply chain resilience should be treated as a network capability built through visibility, defined responsibilities, quality agreements, escalation pathways, and proactive governance before disruptions occur.

Pharmaceutical supply chains have become more dependent on networks of specialized external partners. Contract manufacturers, raw-material suppliers, testing laboratories, packaging providers, logistics partners, and other vendors may each contribute to the development, manufacture, release, and distribution of a product. These networks can provide flexibility, capacity, technical expertise, and geographic reach, but they also make the supply chain harder to see and harder to coordinate.

The challenge is not outsourcing itself. External partners are essential to much of modern pharmaceutical development and manufacturing. The issue is that outsourced supply networks can become fragmented when visibility, quality oversight, communication pathways, supplier controls, and escalation processes are not designed across the full chain. A sponsor may have confidence in each direct partner while still lacking a complete view of the dependencies among them.

This distinction is critical for resilience. A supply chain can appear stable under routine conditions but reveal weaknesses under stress. A supplier delay, quality event, analytical issue, logistics disruption, capacity constraint, or unexpected demand shift may require rapid coordination across several organizations. If the sponsor cannot quickly identify where the problem originated, which activities are affected, who can approve changes, and what quality or regulatory consequences may follow, the disruption can grow beyond its initial cause.

Supply chain resilience therefore depends on more than backup suppliers or inventory buffers. It also depends on governance. Sponsors need visibility into critical nodes, clear responsibilities across outsourced relationships, timely information flow, reliable quality systems, and the ability to escalate and resolve issues across organizational boundaries.

The drug supply chain has become longer, more complex, and more fragmented as companies have located more production overseas and increased their use of contract manufacturers. That complexity can limit manufacturers’ ability to increase production after a disruption. For pharmaceutical companies relying on outsourced networks, this creates a practical resilience challenge: disruptions are harder to manage when production, testing, materials, documentation, and decision-making are distributed across several organizations.

Contract manufacturing can involve many activities, including formulation, fill/finish, chemical synthesis, cell culture and fermentation, analytical testing, packaging and labeling, and sterilization. Each activity may be performed by a different provider or by a provider that depends on its own suppliers and subcontractors. As the number of organizations involved increases, so does the importance of defining responsibilities, communication mechanisms, and quality expectations.

Fragmentation is not only a structural issue. It is also an information problem. Sponsors may know who manufactures the product but have less visibility into upstream suppliers, alternate material sources, analytical dependencies, equipment constraints, subcontracted testing, or logistics bottlenecks. When the network functions normally, those gaps may remain hidden. During a disruption, they can slow root-cause assessment and recovery planning.

A fragmented network can also blur the boundary between operational and quality risk. A late material shipment may create manufacturing delays. A supplier quality issue may require additional testing, investigation, or change control. A testing delay may affect batch release. A packaging or logistics disruption may affect clinical or commercial supply. Each event may begin in one part of the network but create consequences elsewhere.

A systematic review of pharmaceutical supply chain risks identified 50 main risks across seven categories: supply and supplier, organization and strategy, financial, logistic, political, market, and regulatory.¹ Supply and supplier risks accounted for 40% of the risks defined in the reviewed studies, while organization and strategy risks accounted for 28%. These findings support an important point for outsourced manufacturing networks: supplier risk is not a narrow procurement issue. It is a core operational risk.

Relevant supply and supplier risks include supplier relationships, ordering cycle time, raw-material quality, supplier flexibility, contract and agreement issues, supplier customization, good manufacturing practice (GMP) certification of suppliers, delivery reliability, supplier quality-management systems, and timely delivery. Organization and strategy risks include planning and operation issues, worker skill, information flow, and stock visibility. Fragmentation was also identified as a pharmaceutical supply chain risk in one of the studies included in the review.

These risks are highly relevant to outsourced networks because sponsors may not control every supplier directly. A contract development and manufacturing organization (CDMO) may manage some supplier relationships. A raw-material issue may originate several steps upstream. A packaging provider may depend on its own material suppliers. A testing provider may rely on specialized reagents, equipment, or subcontracted services. The sponsor’s ability to respond depends on how much visibility it has into those dependencies before problems occur.

The review also concluded that many pharmaceutical supply chain risks were internal risks related to mismanagement of processes, people, and functions, and could be addressed through suitable mitigation strategies.¹ That conclusion is especially useful because it reframes resilience as a management discipline. Not every disruption can be prevented, but sponsors can reduce vulnerability by improving process discipline, information flow, supplier oversight, and cross-functional coordination.

Supplier qualification is therefore only the starting point. Pharma companies need to understand how suppliers are monitored, how changes are controlled, how supplier quality issues are escalated, how alternate sources are evaluated, and how supplier information connects to manufacturing, quality, regulatory, and supply chain planning. Without that integration, a supplier relationship that appears adequate on paper may not support resilient execution.

Quality problems are a central source of supply chain vulnerability. The U.S. Food and Drug Administration’s (FDA) drug-shortage analysis identifies market failure to reward mature quality management systems as a root cause of shortages.² The FDA’s 2020 update found quality problems were responsible for 62% of drugs that went into shortage between 2013 and 2017.³

For outsourced networks, this means that quality-system maturity is not only a compliance concern. It is a supply continuity concern. A weak quality system at one node can affect the entire chain. A deviation, failed inspection, documentation problem, contamination event, process inconsistency, or supplier-quality issue can delay production or release, reduce available capacity, and force the pharma company to make difficult decisions under time pressure.

Purchasers may have limited information about facility quality management and little information linking purchased drugs to the facilities where they were manufactured.² When quality information is limited or difficult to interpret, pharma companies may struggle to distinguish between providers with similar apparent capabilities but different levels of operational robustness.

Quality agreements are one tool for addressing this challenge. Quality agreements can be used to define, establish, and document manufacturing activities among parties involved in contract drug manufacturing subject to current good manufacturing practice (CGMP) requirements.⁴ Quality agreements should describe materials or services, quality specifications, and communication mechanisms between the owner and contract facility, and they should define manufacturing responsibilities and communication processes for quality-related activities.

These agreements become more important as outsourced networks become more complex. They help clarify how deviations will be reported, investigated, documented, and resolved; how audits and inspections will be handled; how findings and regulatory correspondence will be communicated; and how product and process knowledge will move between owner and contractor. In a resilience context, these provisions are not merely compliance documentation. They define how the network will respond when quality issues threaten supply.

Technology transfer is one of the most important points of vulnerability in outsourced manufacturing networks. A process, method, or product may move from development to manufacturing, from one site to another, from an internal team to a CDMO, or from one external provider to another. Each transfer requires more than the exchange of documents. It requires the movement of product, process, analytical, equipment, quality, and operational knowledge.

World Health Organization (WHO) guidance on technology transfer in pharmaceutical manufacturing covers organization and management, production transfer, analytical method transfer, premises and equipment, documentation, qualification, and validation.⁵ The International Society of Pharmaceutical Engineering’s (ISPE) technology-transfer framework includes assembling a transfer team, developing a charter, preparing a transfer proposal and plan, executing the transfer, developing qualification, finalizing transfer, and conducting review.⁶ These elements show that technology transfer should be a structured process, not an informal handoff.

In an outsourced network, technology-transfer weaknesses can become supply chain weaknesses. If a receiving site lacks full context for a process, it may repeat development work, misinterpret critical parameters, struggle with comparability, or encounter avoidable deviations. If an analytical method transfers without sufficient understanding of its limitations, release testing or stability testing may become a bottleneck. If prior process history is not communicated, a known sensitivity may reappear as a new problem.

Knowledge continuity is also important after transfer. Knowledge management is a systematic approach to acquiring, analyzing, storing, and disseminating product, process, and component information.⁷ FDA guidance states that quality agreements should indicate how owners will transfer product and process development knowledge to contract facilities and how contract facilities should share product quality information back to owners.⁴ These expectations are directly connected to resilience because recovery from disruption requires reliable knowledge about the product and process.

Staff turnover makes knowledge continuity even more important. If key knowledge resides primarily with individual employees at the sponsor, CDMO, or supplier, a personnel change can weaken the network’s ability to respond. Sponsors should therefore treat knowledge management as a supply chain control. Process history, analytical rationale, prior deviations, raw-material considerations, equipment constraints, and change-control decisions should remain accessible even when work moves between organizations or teams change.

Supply chain resilience depends on how quickly accurate information moves. Demand surges, capacity reductions, and coordination failures are the main causes of medical-product supply chain shortages.³ A supply network can have capacity and materials but still fail to respond effectively if information does not move quickly enough to support decisions.

The systematic review of pharmaceutical supply chain risks identified information flow and stock visibility among organization and strategy risks.¹ These risks can be especially challenging in outsourced networks because no single organization may control all relevant data. A sponsor may receive production updates from one provider, material information from another, quality information from a third, and logistics information from another. If these streams are not connected, the sponsor may lack a real-time view of supply risk.

Poor information flow can turn a manageable issue into a larger disruption. A supplier delay may not be communicated until it affects a manufacturing slot. A quality concern may not be escalated until additional testing is required. A logistics problem may not be visible until product release is complete but distribution is delayed. An inventory constraint may be known locally but not incorporated into program-level planning.

The risk increases when decisions require coordination across several providers. If a material must be replaced, a pharma company may need input from supplier quality, process development, analytical development, manufacturing, quality assurance, regulatory affairs, and the CDMO. If a site cannot produce as planned, the company may need to evaluate alternate capacity, technology transfer requirements, comparability considerations, and regulatory implications. If a batch release is delayed, clinical operations or commercial supply teams may need to adjust downstream plans.

This is why visibility should be designed into the network. Pharma companies need defined reporting expectations, performance metrics, escalation thresholds, and decision rights. They also need clarity on how information from suppliers, CDMOs, laboratories, packaging providers, and logistics partners will be consolidated into a usable view of supply risk. Without that visibility, resilience depends too heavily on late-stage reaction.

Quality agreements are often discussed as tools for compliance, but they also support resilience in outsourced supply networks. Quality agreements define and document manufacturing activities among parties involved in contract drug manufacturing subject to CGMP, including communication mechanisms, manufacturing responsibilities, quality-related activities, audits, inspections, deviations, and other key elements.⁴ Those provisions become critical when a disruption or quality event requires rapid coordination.

A strong quality agreement helps answer practical questions before stress occurs. Who reports a deviation? Who investigates it? What information must be shared with the sponsor? Who approves corrective and preventive action? How are inspection findings communicated? How are changes assessed? How is product quality information shared back to the owner? How is development knowledge transferred to the contract facility? The FDA supports using quality agreements to address these kinds of responsibilities and communication processes.⁴

In a fragmented network, these questions may apply across multiple relationships. A pharma company may have one agreement with a drug substance manufacturer, another with a drug product manufacturer, another with a testing laboratory, and another with a packaging provider. If those agreements are not aligned, an issue that crosses vendor boundaries may expose gaps between them. One provider may have a deviation process that does not align with another provider’s change-control timeline. One provider may communicate findings quickly, while another may require several approval steps before sharing information. One agreement may address audits in detail, while another may provide less practical visibility.

Quality agreements should therefore be reviewed not only as bilateral documents but as part of the larger supply network. Pharma companies should understand how each agreement contributes to overall visibility, escalation, documentation, and recovery. The value of a quality agreement is not limited to defining what each party does under normal conditions. It also lies in defining how parties behave when normal conditions fail.

ICH Q10 reinforces this broader view by stating that the pharmaceutical quality system should include appropriate processes, resources, and responsibilities to assure the quality of outsourced activities and purchased materials.⁷ In resilience terms, that means outsourced quality cannot be managed as a set of disconnected vendor files. It must function as a system that allows the sponsor to detect risk, understand impact, coordinate response, and maintain control.

Supply chain governance should be built before disruption because the middle of a disruption is the worst time to define responsibilities. Sponsors need to know which providers are critical, which materials have limited alternatives, which processes are difficult to transfer, which analytical methods could create release bottlenecks, which subcontractors perform important work, and which decisions require quality or regulatory approval.

The first governance requirement is supplier and vendor visibility. Sponsors should understand not only their direct relationships but also the critical dependencies behind those relationships. That includes key suppliers, subcontractors, testing dependencies, logistics constraints, and site-specific capabilities. Where visibility is limited, sponsors should evaluate whether contractual terms, quality agreements, reporting processes, or supplier-review practices need to be strengthened.

The second requirement is defined escalation. Quality issues, supplier delays, delivery failures, capacity constraints, and material changes should have clear escalation thresholds. Sponsors should not rely on informal judgment alone to determine when an issue becomes urgent. Escalation pathways should identify who must be informed, what information is required, who has decision authority, and how follow-up will be documented.

The third requirement is knowledge continuity. Technology transfer, process history, analytical method rationale, prior deviations, supplier qualification information, and change-control history should remain accessible across the network. This is especially important when work shifts between sites or vendors, when teams change, or when a disruption requires rapid evaluation of alternatives.

The fourth requirement is risk-based prioritization. Not every vendor, material, or process step carries the same supply risk. Sponsors should focus the strongest governance on critical suppliers, constrained materials, specialized manufacturing capabilities, release-critical testing, high-risk subcontracted activities, and processes with limited transferability. This allows oversight resources to be directed where they matter most.

The fifth requirement is periodic reassessment. Outsourced supply networks change over time. A supplier that was low-risk during early development may become more important as the program advances. A CDMO relationship may expand from development to clinical supply. A material that was easy to source at small scale may become more constrained as demand grows. A quality agreement drafted early in the relationship may no longer reflect the work being performed. Governance must evolve with the program.

Pharmaceutical supply chain resilience is often discussed in terms of redundancy, inventory, alternate suppliers, or geographic diversification. Those tools may be important, but they are not sufficient when the underlying network lacks visibility and coordination. A backup supplier does not solve a problem if the sponsor discovers the need too late. Additional inventory does not correct a quality-system weakness. Alternate capacity may not be useful if technology transfer requirements, analytical methods, or regulatory implications have not been considered.

In outsourced networks, resilience is a network capability. It depends on the sponsor’s ability to see across suppliers and vendors, receive timely information, understand dependencies, evaluate quality and regulatory consequences, and coordinate action across organizations. It also depends on the maturity of each provider’s quality systems and the clarity of the agreements connecting them.

This requires a broader view of outsourcing strategy. Vendor selection should consider technical capability, capacity, price, and timeline, but it should also consider visibility, communication, quality maturity, supplier controls, documentation, technology-transfer readiness, and responsiveness under stress. A provider that performs well under routine conditions may still create risk if it cannot support transparent escalation or integrated recovery planning.

The goal is not to eliminate outsourced complexity. That would be unrealistic in modern pharmaceutical development and manufacturing. The goal is to make complexity visible and governable. Sponsors that understand their network, define responsibilities, maintain quality and knowledge continuity, and build escalation pathways before disruption are better positioned to protect supply.

Outsourced manufacturing and supply networks can provide significant value, but only when sponsors manage them as interconnected systems. Fragmentation becomes most costly when it remains unseen until a problem occurs. By treating resilience as a function of governance, not only redundancy, pharma companies can reduce the risk that a supplier issue, quality event, technology-transfer gap, or coordination failure will cascade across the network.

1. Jaberidoost, Mona, et al. “Pharmaceutical Supply Chain Risks: A Systematic Review.” DARU Journal of Pharmaceutical Sciences. 21:69 (2013).

2. “Drug Shortages: Root Causes and Potential Solutions.” U.S. Food and Drug Administration. Oct.2019.

3. Shore, C, et al., eds. “Causes and Consequences of Medical Product Supply Chain Failures.” Building Resilience into the Nation’s Medical Product Supply Chains. National Academies Press, Chapter 4 (2022).

4. Contract Manufacturing Arrangements for Drugs: Quality Agreements; Guidance for Industry. U.S. Food and Drug Administration. Nov. 2016.

5. WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing. WHO Technical Report Series. 961: 285–309 (2011).

6.  “Pharmaceutical Technology Transfer Training Course.” International Society for Pharmaceutical Engineering. Accessed 3 Jun. 2026.

7. ICH Q10 Pharmaceutical Quality System. International Council for Harmonisation. Step 4 version, 4 Jun. 2008.